Author

Irina Rozhkova

Observed names: I Rozhkova, I. A. Rozhkova, I. Rozhkova

OpenAlex ID: A5019801281

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

2022 · Miranda Gogishvili, Tamar Melkadze, et al. · Nature Medicine · 316

PDF

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

2023 · Tamta Makharadze, Miranda Gogishvili, et al. · Journal of Thoracic Oncology · 112

PDF

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

2024 · David R. Spigel, Afshin Dowlati, et al. · Journal of Clinical Oncology · 45

LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

2021 · M. Gogishvili, T. Melkadze, et al. · Annals of Oncology · 18

PDF

Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3

2023 · Tamta Makharadze, Ruben G. W. Quek, et al. · Cancer · 16

PDF

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial

2024 · Ana Baramidze, Tamta Makharadze, et al. · Lung Cancer · 11

PDF

MA10.09 Cemiplimab Plus Chemotherapy vs Chemotherapy in Advanced NSCLC: 5-Year Results from Phase3 EMPOWER-Lung 3 Part 2 Trial

2025 · A. Baramidze, T. Makharadze, et al. · Journal of Thoracic Oncology · 2

954P Cemiplimab with platinum-based chemotherapy (chemo) for first-line (1L) locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 3 subgroup analysis

2022 · E. Kalinka-Warzocha, M. Gogishvili, et al. · Annals of Oncology · 2

50 Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: Longer follow-up results from the phase III EMPOWER-Lung 3 trial

2023 · T. Makharadze, M. Gogishvili, et al. · Journal of Thoracic Oncology · 1

PDF

318P EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

2022 · M. Gogishvili, T. Melkadze, et al. · Annals of Oncology · 1

93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial

2021 · T. Makharadze, R.G. Quek, et al. · Annals of Oncology · 1

PDF

Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial

2026 · Ana Baramidze, Tamta Makharadze, et al. · Journal of Thoracic Oncology

Cemiplimab plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer with PD-L1≥1%: 5‑year update of EMPOWER-Lung 3 results

2026 · P Hoffknecht, M Gogishvili, et al. · Pneumologie

125P Cemiplimab plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer with PD-L1 ≥1%: 5-year update of EMPOWER-Lung 3 results

2025 · M. Gogishvili, T. Makharadze, et al. · Immuno-Oncology Technology

Results of an international, double-blind, randomized, phase III clinical trial to compare the efficacy and safety of a biosimilar pertuzumab (BCD-178) with reference pertuzumab in patients with HER2-positive breast cancer

2025 · L. G. Zhukova, E. V. Artamonova, et al. · Medical alphabet

Results of phase III clinical trial of novel biosimilar of pembrolizumab (RPH-075).

2025 · Ilya Pokataev, Konstantin Penkov, et al. · Journal of Clinical Oncology

1495P Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results

2023 · A. Baramidze, T. Makharadze, et al. · Annals of Oncology

PDF

Works count: 17

Citation count: 525

H-index: 6

I10-index: 6